Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14066214 | 0.82 | PTGDR2 (0.60) | TSHRSMN1; SMN2TDP1 | |
| SCHEMBL1641613 | 0.80 | TSHR (0.57) | TSHRLMNAHPGDKMT2ATDP1 | |
| SCHEMBL29954739 | 0.79 | ALDH1A1 (0.59) | TSHRLMNAHTTHPGDALDH1A1 | |
| SCHEMBL9187547 | 0.79 | TSHR (0.56) | TSHRLMNAHPGDKMT2ATDP1 | |
| SCHEMBL11078865 | 0.77 | PTPN11 (0.52) | TSHRLMNAHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL11774385 | 0.76 | PTPN11 (0.58) | TSHRLMNAHTTSMN1; SMN2MEN1 | |
| SCHEMBL11775746 | 0.75 | PTPN11 (0.64) | TSHRLMNAHTTHPGDALDH1A1 | |
| SCHEMBL13951307 | 0.74 | ALDH1A1 (0.50) | TSHRLMNAHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL5325696 | 0.74 | PTPN11 (0.67) | LMNAHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL9500879 | 0.74 | PTPN11 (0.67) | LMNAHPGDALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080213187-A1 | NOVEL CASCADE POLYMER COMPLEXES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | EPIX PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
| US-7211241-B2 | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-01 | — | — | US | disclosed |
| US-7211241-B2 | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080213187-A1 | NOVEL CASCADE POLYMER COMPLEXES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PGF, F13A1, F11 | TSHR 3157/4885LMNA 323/4885HTT 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.